Clinical Trial Update: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults [Phase 2]

View source ↗

Summary

An extension of a Phase 2 trial evaluating the booster immune response to the Vi-CRM197 typhoid vaccine in adults; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-CRM197 (CRM197-conjugated Vi polysaccharide vaccine)

Snippet

Sponsor: Novartis | Conditions: Typhoid Fever | Phase 2 | Status: COMPLETED | Results posted: 2014-03-24